HIV and Hepatitis Virus Resistance to Antivirals: Review of Data from the Xix International HIV and Hepatitis Virus Drug Resistance Workshop and Curative Strategies
Free accessCase reportFirst published online February, 2011
HIV and Hepatitis Virus Resistance to Antivirals: Review of Data from the Xix International HIV and Hepatitis Virus Drug Resistance Workshop and Curative Strategies
The XIX International HIV and Hepatitis Virus Drug Resistance Workshop offered scientists, clinical investigators, physicians and others an opportunity to present study results selected in a rigorous peer-review process and to discuss those data in an open forum. In 2010, Workshop organizers expanded the programme to include hepatitis B and C viruses, reasoning that workers in all three fields could benefit from shared experience, positive and negative. Slide sessions at the 2010 Workshop focused on hepatitis virus resistance to current and experimental antivirals; epidemiology of HIV resistance; HIV pathogenesis, fitness and resistance; resistance to new antiretrovirals; markers of response to HIV entry inhibitors; HIV persistence, reservoirs and elimination strategies; application of new viral sequencing techniques; and mechanisms of HIV drug resistance. This article summarizes all slide presentations at the Workshop.
References
1.
RossL.L., WineB., HortonJ.H.Prevalence of HIV-1 drug resistance-associated mutations in a large cohort of antiretroviral-naive HIV-infected individuals in the USA from 2000–2009. Antivir Ther2010; 15Suppl 2: A50.
2.
AssoumouI., DescampsD., YerlyS.Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/ml in 2009: a French nationwide study. Antivir Ther2010; 15Suppl 2: A185.
3.
BarthR.E., AitkenS.C., TempelmanH.Rapid accumulation of drug resistance and loss of therapeutic options precede WHO-defined criteria for treatment failure. Antivir Ther2010; 15Suppl 2: A51.
4.
WallisC.L., VianaR., St JohnE.P.Presence of low abundance drug-resistant mutations in recently infected HIV-1 subtype C patients from South Africa. Antivir Ther2010; 15Suppl 2: A35.
5.
KarasiJ.C., MusoneraF., ServaisJ.Y.HIV-1 molecular epidemiology and prevalence of drug resistance in treatment-naive and HAART-treated patients between 2003 and 2009 in Rwanda. Antivir Ther2010; 15Suppl 2: A143.
6.
AghokengA.F., KouanfackC., LaurentC.Frequency of antiretroviral resistance mutations among ART-naive HIV-1-infected populations in rural areas from Cameroon. Antivir Ther2010; 15Suppl 2: A151.
7.
CharpentierC., GodyJ-C, MbitikonO., MoussaS., BélecL.Prevalence of HIV-1 drug resistance in HIV-1-infected children treated in Bangui, Central African Republic, using plasma and dried blood spot samples. Antivir Ther2010; 15Suppl 2: A147.
8.
DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. (Updated 10 January 2011. Accessed 23 February 2011.) Available from http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf.
Cozzi-LepriA., PhillipsA.N., RuizL.Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. AIDS2007; 21: 721–732.
11.
JohnsonV.A., Brun-VézinetF., ClotetB.Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med2010; 18: 156–163.
12.
Stanford University HIV Drug Resistance Database.The World Health Organization 2009 list of mutations for surveillance of transmitted drug resistant HIV strains. (Accessed 23 February 2011.) Available from http://hivdb.stanford.edu./pages/WHOResistanceList.html.
13.
LipscombJ.T., OwenS.M., JohnsonJ.A.Dynamic expression of HIV-1 drug resistance mutations during acute infection. Antivir Ther2010; 15Suppl 2: A47.
14.
ProsperiM.C.F., FantiI., CiccozziM.Large-scale phylodynamics of HIV-1 in Italy: analysis on epidemic and resistance transmission. Antivir Ther2010; 15Suppl 2: A48.
15.
HarrisonL., CastroH., CaneP.The effect of transmitted HIV-1 drug resistance on pre-therapy viral load. Antivir Ther2010; 15Suppl 2: A49.
16.
ShaferR.W., RheeS.Y., PillayD.HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS2007; 21: 215–223.
17.
TaiwoB., GallienS., AgaE.HIV-1 drug resistance evolution during persistent near target viral suppression. Antivir Ther2010; 15Suppl 2: A38.
18.
SchackmanB.R., RibaudoH.J., KrambrinkA., HughesV., KuritzkesD.R., GulickR.M.Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095. J Acquir Immune Defic Syndr2007; 46: 547–554.
19.
HaasD.W., RibaudoH.J., KimR.B.Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS2004; 18: 2391–2400.
20.
CongM., YoungpairojA.S., ZhengQ.Complete protection against rectal transmission of an emtricitabine (FTC)-resistant SHIV162p3M184V mutant by intermittent prophylaxis with Truvada. Antivir Ther2010; 15Suppl 2: A39.
21.
García-LermaJ.G., CongM.E., MitchellJ.Intermittent prophylaxis with oral Truvada protects macaques from rectal SHIV infection. Sci Transl Med2010; 2: 14ra4.
22.
GalliA., NikolaitchikO., ChenJ.Factors affecting the emergence of intersubtype recombinants in HIV-1 population. Antivir Ther2010; 15Suppl 2: A40.
23.
JosefssonL., PalmerS., CasazzaJ.Analysis of HIV DNA molecules in paired peripheral blood and lymph node tissue samples from chronically infected patients. Antivir Ther2010; 15Suppl 2: A41.
24.
NeherR.A., LeitnerT.Recombination rate and selection strength in HIV intra-patient evolution. PLOS Comput Biol2010; 6: e1000660.
25.
SmithA.J., LiQ., WietgrefeS.W., SchackerT.W., ReiilyC.S., HaaseA.T.The relationship between virus replication and gene expression in lymphatic tissue during HIV-1 infection. Antivir Ther2010; 15Suppl 2: A42.
26.
MillerM., FransenS., HuangW.Temporal order of resistance emergence for lamivudine/emtricitabine, efavirenz and raltegravir in treatment-naive patients. Antivir Ther2010; 15Suppl 2: A11.
27.
MarkowitzM., NguyenB.Y., GotuzzoE.Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr2007; 46: 125–133.
28.
LennoxJ.L., DeJesusE., LazzarinA.Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet2009; 374: 796–806. [Erratum in Lancet 2009; 374: 786. Lancet 2009; 374: 2054].
29.
EronJ.J., YoungB., CooperD.A.Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomized controlled trials. Lancet2010; 375: 396–407.
30.
VispoE., BarreiroP., BlancoF.Impact of prior NRTI failure in the ODIS trial, a study conducted in HIV+ patients on undetectable viraemia on protease inhibitors who switched to raltegravir once daily versus twice daily. Antivir Ther2010; 15Suppl 2: A123.
31.
YoshinagaT., Kanamori-KoyamaM., SekiT., SatoA., FujiwaraT.Strong inhibition of wild-type and integrase inhibitor (INI)-resistant HIV integrase (IN) strand transfer reaction by the novel INI S/GSK1349572. Antivir Ther2010; 15Suppl 2: A12.
32.
JohnsB., KawasujiT., TaishiT.The discovery of S/ GSK1349572: a once daily next generation integrase inhibitor with a superior resistance profile.17th Conference on Retroviruses and Opportunistic Infections. 16–19 February 2010, San Francisco, CA, USA. Abstract 55.
33.
SekiT., KobayashiM., Wakasa-MorimotoC.S/GSK1349572 is a potent next generation HIV integrase inhibitor and demonstrates a superior resistance profile substantiated with 60 integrase mutant molecular clones.17th Conference on Retroviruses and Opportunistic Infections. 16–19 February 2010, San Francisco, CA, USA. Abstract 555.
34.
ClotetB., KatlamaC., LalezariJ.HIV integrase resistance profiles and S/GSK1349572 baseline phenotypic susceptibility for individuals experiencing virological failure on raltegravir and enrolling in the VIKING Phase IIb pilot study (ING112961). Antivir Ther2010; 15Suppl 2: A61.
35.
HightowerK.E., WangR., UnderwoodM.R.S/GSK1349572 demonstrates significantly slower dissociation rates than raltegravir when comparing wild-type and raltegravir-resistant integrase protein. Antivir Ther2010; 15Suppl 2: A16.
36.
GroblerJ.A., McKennaP.M., LyS.Functionally irreversible inhibition of integration by slowly dissociating strand transfer inhibitors.10th International Workshop on Clinical Pharmacology of HIV Therapy. 15–17 April 2009, Amsterdam, the Netherlands. Abstract O-10.
37.
SatoA., KobayashiM., YoshinagaT.S/GSK1349572 is a potent next generation HIV integrase inhibitor.5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 19–22 July 2009, Cape Town, South Africa. Abstract WEPEA097.
38.
MullinsJ.I., HeathL., HughesJ.P.Mutations based on viral decay acceleration in the HIV-1 genomes of a clinical population treated with the mutagenic nucleoside KP1461. Antivir Ther2010; 15Suppl 2: A9.
39.
Grande-PérezA., LázaroE., LowensteinP., DomingoE., ManrubiaS.C.Suppression of viral infectivity through lethal defection. Proc Natl Acad Sci U S A2005; 102: 4448–4452.
40.
MarchandB., KirbyK.A., SietsemaD.The crystal structure of EFdA-resistant HIV-1 reverse transcriptase reveals structural changes in the polymerase active site. Antivir Ther2010; 15Suppl 2: A10.
41.
MarchandB., MichailidisL., KodamaE.I.Mechanisms of inhibition and resistance to translocation deficient reverse transcriptase inhibitors. Antivir Ther2009; 14Suppl 1: A22.
42.
SierraS., BalduinM., ZazziM.Pairwise comparison of genotypic tropism prediction between 1 reference centre and 10 European laboratories. Antivir Ther2010; 15Suppl 2: A22.
43.
ChapmanD., ValdezH., LewisM.Clinical, virological and immunological characteristics of patients with discordant phenotypic and genotypic (ultra-deep sequencing) tropism test results: analysis of tropism calls in MOTIVATE and 1029. Antivir Ther2010; 15Suppl 2: A21.
44.
GulickR.M., LalezariJ., GoodrichJ.Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med2008; 359: 1429–1441.
45.
SaagM., GoodrichJ., FätkenheuerG.A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis2009; 199: 1638–1647.
46.
CooperD.A., HeeraJ., GoodrichJ.Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis2010; 201: 803–813.
47.
SwensonL.C., ChuiC.K.S., BrummeC.J.Genotypic analysis of V3 in patients experiencing virological failure on maraviroc-containing regimens and correlation with pre-treatment ‘deep’ sequencing results. Antivir Ther2010; 15Suppl 2: A17.
48.
StrizkiJ.M., McNicholasP., MannP.Use of the enhanced sensitivity tropism assay (ESTA) to predict on-treatment detection of CXCR4-using virus and impact on virological outcomes in a vicriviroc (VCV) Phase II treatment-experienced study (VICTOR-E1). Antivir Ther2010; 15Suppl 2: A18.
49.
SuleimanJ., ZingmanB.S., DiazR.S.Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 Phase 2 trial. J Infect Dis2010; 201: 590–599.
50.
GatheJ., DiazR., FatkenheuerG.Phase 3 trials of vicriviroc in treatment-experienced subjects demonstrate safety but not significantly superior efficacy over potent background regimens alone.17th Conference on Retroviruses and Opportunistic Infections. 16–19 February 2010, San Francisco, CA, USA. Abstract 54LB.
51.
SvicherV., AlteriC., ArteseA.Specific genetic signatures in V3 base can modulate coreceptor usage in vivo, the interaction with neutralizing antibodies and HIV-1 cytopathic effect. Antivir Ther2010; 15Suppl 2: A20.
52.
HuangC.C., LamS.N., AcharyaP.Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science2007; 317: 1930–1934.
53.
HuangW., FrantzellA., TomaJ.Defining evolutionary pathways and genetic barriers to CXCR4-mediated entry by HIV type-1. Antivir Ther2010; 15Suppl 2: A19.
54.
WightmanF., SalehS., SolomonA.The histone deacetylase inhibitors SAHA, MS-275, LBH589 and MCT3 are able to induce HIV-1 transcription with differing potencies in chronically infected cell lines and latently infected primary CD4+ T-cells. Antivir Ther2010; 15Suppl 2: A43.
55.
KearneyM., SpindlerJ., ShaoW.Rebound HIV-1 viraemia after cessation of long-term suppressive antiretroviral therapy has low genetic diversity and little divergence from pre-therapy virus populations. Antivir Ther2010; 15Suppl 2: A46.
56.
WagnerT.A., McKernanJ.L., TobinN.H., FrenkelL.M.Emergence of monotypic HIV-1 DNA during ART suggests proliferation of cells with integrated HIV DNA provirus may sustain infection. Antivir Ther2010; 15Suppl 2: A45.
57.
KoelschK.K., XuY., BaileyM.Most HIV DNA in PBMC is present in non-gut homing, resting central memory CD4 T-cells. Antivir Ther2010; 15Suppl 2: A44.
58.
BrenchleyJ.M., SchackerT.W., RuffL.E.CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med2004; 200: 749–759.
59.
ChunT.W., NickleD.C., JustementJ.S.Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis2008; 197: 714–720.
60.
ZaundersJ.J., IpS., MunierM.L.Infection of CD127+ (interleukin-7 receptor+) CD4+ cells and overexpression of CTLA-4 are linked to loss of antigen-specific CD4 T cells during primary human immunodeficiency virus type 1 infection. J Virol2006; 80: 10162–10172.
61.
ShaferR.W.Next-generation deep-sequencing technologies for virus quasispecies analysis: implications for detecting minority drug-resistant variants. Antivir Ther2010; 15Suppl 2: A22.
62.
BrennerB.G., OliveiraM., Doualla-BellF.HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS2006; 20: F9–F13.
63.
CoutsinosD., InvernizziC.F., XuH.Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1. J Virol2009; 83: 2029–2033.
64.
InvernizziC.F., CoutsinosD., OliveiraM., MoisiD., BrennerB.G., WainbergM.A.Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the K65R resistance mutation in HIV-1 subtype C. J Infect Dis2009; 200: 1202–1206.
65.
KozalM.J., ChiarellaJ., St JohnE.P.Prevalence of low-level variants with RT K65R among different HIV subtypes and the effects of ARV-exposure on variant levels. Antivir Ther2010; 15Suppl 2: A34.
66.
LatailladeM., ChiarellaJ., YangR.Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naive subjects in the CASTLE study. PLoS ONE2010; 5: e10952.
67.
VargheseV., WangE., BabrzadehF.Nucleic acid template and the risk of a PCR-induced HIV-1 drug resistance mutation. PLoS ONE2010; 5: e10992.
68.
ShaoW., BoltzV.F., SpindlerJ.E.Reduced PCR-based recombination for HIV-1 drug resistance mutation linkage determination by 454 pyrosequencing. Antivir Ther2010; 15Suppl 2: A33.
69.
The SPREAD-programme. Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS2008; 22: 625–635.
70.
PingenM., van der EndeM.E., WensingA.M.J., BoucherC.A., SchuttenM.Single transmitted drug resistance mutations: not always an indicator of transmission of more extensive resistance profiles. Antivir Ther2010; 15Suppl 2: A36.
71.
WittkopL. the EuroCoord-CHAIN project team. Impact of transmitted drug resistance on virological response to initial combination antiretroviral therapy. Antivir Ther2010; 15Suppl 2: A124.
72.
SimenB.B., BravermanM.S., AbbateI.A multicentre collaborative study on HIV drug resistance testing using 454 massively parallel pyrosequencing. Antivir Ther2010; 15Suppl 2: A37.
73.
BandaranayakeR.M., MittalS., KingN.M., Prabu-JeyabalanM., NalamM.N.L., SchifferC.A.Differential resistance in HIV-1 protease: the role of residue 50 in pathways for amprenavir/ darunavir and atazanavir resistance. Antivir Ther2010; 15Suppl 2: A14.
74.
CoutsinosD., InvernizziC.F., MoisiD.The K65R mutation in subtype B and C HIV-1: rates of development and the implications of template-specific dislocation mutagenesis. Antivir Ther2010; 15Suppl 2: A13.
75.
NalamM.N.L., AliA., ReddyG.S.K.K., AnjumS.G., RanaT.M., SchifferC.A.Substrate envelope based design of potent HIV-1 protease inhibitors resilient to resistance. Antivir Ther2010; 15Suppl 2: A15.
76.
NalamM.N., AliA., AltmanM.D.Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance. J Virol2010; 84: 5368–5378.
77.
LocarniniS.A.Hepatitis B: new treatments and drug resistance. Antivir Ther2010; 15Suppl 2: A4.
78.
PawlotskyJ-M. Hepatitis C: new treatments and drug resistance. Antivir Ther2010; 15Suppl 2: A5.
79.
SvicherV., CentoV., SalpiniR.The HBV genetic barrier and the overlapping structure of HBV genome synergistically modulate drug resistance emergence and immune-escape potential of HBV genotypes. Antivir Ther2010; 15Suppl 2: A23.
80.
LamA.M., BansalS., EspirituC., OttoM.J., FurmanP.A.Selection and characterization of hepatitis C virus replicons using combination of NS3 protease and NS5B non-nucleoside inhibitors or combination of NS5B nucleotide inhibitors. Antivir Ther2010; 15Suppl 2: A28.
81.
RomanoK., AliA., SchifferC.Avoiding drug resistance against HCV NS3/4A protease inhibitors. Antivir Ther2010; 15Suppl 2: A25.
82.
KwongA.D., McNairL., JacobsonI., GeorgeS.Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors. Curr Opin Pharmacol2008; 8: 522–531.
83.
BartelsD.J., SullivanJ.C., ZhangE.Z.Characterization of resistant variants in treatment-experienced genotype-1 HCV patients receiving telaprevir/peginterferon/ribavirin in Phase II clinical trials. Antivir Ther2010; 15Suppl 2: A29.
84.
ChevaliezS., RodriguezC., Ahmed-BelkacemA.Molecular characterization of HCV resistance to telaprevir, a novel, potent HCV protease inhibitor. Antivir Ther2010; 15Suppl 2: A31.
85.
BarnardR.J.O., Adeniji-AdeleA., WiedmannR.Analysis of resistance in virological failures during IFN/RBV therapy post 28 day treatment with MK7009: results through week 24 of the Phase IIa dosing finding study in genotype 1 patients. Antivir Ther2010; 15Suppl 2: A24.
86.
LenzO., VijgenL., VerbinnenT.Deep-sequencing analysis of baseline and on-treatment samples from HCV genotype-1 patients treated for 5 days with TMC435 monotherapy and subsequently retreated with TMC435 in combination with PEG-IFN-α2a/ribavirin. Antivir Ther2010; 15Suppl 2: A27.
87.
WylesD.L., JonesK.A., ValiaevaN., BeadleJ., HostetlerK.Y., SchooleyR.T.Resistance profile of the novel hepatitis C virus (HCV) acyclic nucleoside phosphonate inhibitor ODE-S-MPMPA. Antivir Ther2010; 15Suppl 2: A26.
88.
ZoulimF., LocarniniS.Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology2009; 137: 1593–1608.e1–2.
